PYNG Technologies Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : PYNG Technologies

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Barry Moss who wrote (473)	2/6/1998 8:13:00 PM
From: m. jacobs	Read Replies (1) of 8117

Dear Barry. The medical community suggest that a good field trial would be between 120 to 150 patients. This will provide a very good analysis of the F.A.S.T 1 capability and would provide proof positive of the effectiveness of the device. We do not see this number taking a long time I.E. 60 -120 days or sooner. Remember that we will be working in both the US and Canada and UMMC alone does over 7,000 trauma cases a year. We will have of course started to market the system during field trials and they will also provide motivation for sales. As far as the length of a field trial, this we plan to have in effect for at least 1 year, so that we build the credibility of the benefits of the F.A.S.T 1 to the medical community. So sales activity will have started during field trials but we will continue to deliver to field trial sites for the benefit of collecting data and motivating sales because of the results obtained. The larger the result the greater coverage will will get on the product and therefore attract the "wait and see" crowd. This will in enhance the medical record for world sites to see. Yours truly, Michael Jacobs, President

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next